Win-win cooperation for advancing medical innovation

Peking University Health Science Center, Beijing 100191, China *Correspondence: Jie Qiao: jie.qiao@263.net Received: May 5, 2023; Accepted: May 29, 2023; Published Online: June 6, 2023; https://doi.org/10.59717/j.xinn-med.2023.100002 © 2023 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Citation: Qiao J. (2023). Win-win cooperation for advancing medical innovation. The Innovation Medicine 1(1), 100002. Scientific and technological advancements in medicine have always been highly esteemed worldwide. According to statistics published by the Organization for Economic Cooperation and Development (OECD), global health spending accounted for 9.6% of GDP in 2021. Research and development expenses incurred in “health and environmental projects” comprised 30% to 50% of the total R&D funds available in major developed countries such as the United States and the United Kingdom in 2019. . Novel scientific and technological advancements in medicine will be key areas for innovation and capital investments globally over the next 30 years. These medical innovations are expected to generate new preventative, diagnostic, and treatment methods, as well as health monitoring techniques, new drugs, and devices for managing diseases. These advancements in medicine will not only accelerate existing medical and commercial processes to address people’s ever-changing health demands but also enhance the ability to respond effectively to future emergencies, such as pandemics. Ultimately, the benefits will extend to the entire global community. Achieving this goal requires global cooperation across all levels: governments, medical companies, hospitals, and scientific research institutes must collaborate to create a favorable ecosystem for medical innovation. Governments and companies must partner to tackle the critical challenge of ensuring that innovative products benefit as many individuals as possible.